Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MAAQ NASDAQ:MRNS NASDAQ:PMCB NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMAAQMana Capital Acquisition$4.15-3.3%$3.78$5.35▼$10.25$33.72MN/A33,075 shs9,624 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.89 million shs260 shsPMCBNuvilex$1.07-4.9%$1.06$1.00▼$2.42$7.31M-0.4219,820 shs20,319 shsSNYRSynergy CHC$3.52+2.6%$2.41$0.36▼$10.00$32.35MN/A539,532 shs54,471 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMAAQMana Capital Acquisition0.00%+9.50%+2.22%+968.21%+657.30%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-62.77%PMCBNuvilex+1.82%+0.90%+10.89%-5.49%-45.37%SNYRSynergy CHC+0.88%+10.65%+49.78%+37.75%+1,705.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMRNSMarinus Pharmaceuticals2.0385 of 5 stars3.20.00.04.20.01.70.6PMCBNuvilex3.0106 of 5 stars0.05.00.00.04.40.81.9SNYRSynergy CHC3.9353 of 5 stars3.80.00.00.03.33.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMAAQMana Capital Acquisition 0.00N/AN/AN/AMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsidePMCBNuvilex 0.00N/AN/AN/ASNYRSynergy CHC 3.50Strong Buy$10.00184.09% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77PMCBNuvilexN/AN/AN/AN/A$3.27 per shareN/ASNYRSynergy CHC$34.83M0.93$0.28 per share12.78($1.91) per share-1.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMAAQMana Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AMRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)PMCBNuvilex$330K$0.741.44∞N/AN/A0.51%0.35%8/11/2025 (Estimated)SNYRSynergy CHC$2.12MN/A0.005.97N/AN/A-8.48%12.75%N/ALatest PMCB, MAAQ, SNYR, and MRNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SNYRSynergy CHC$0.07$0.10+$0.03$0.10$9.03 million$8.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMAAQMana Capital AcquisitionN/AN/AN/AMRNSMarinus PharmaceuticalsN/A1.661.47PMCBNuvilexN/A14.2114.21SNYRSynergy CHCN/A1.911.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMAAQMana Capital Acquisition68.44%MRNSMarinus Pharmaceuticals98.80%PMCBNuvilex34.24%SNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipMAAQMana Capital AcquisitionN/AMRNSMarinus Pharmaceuticals5.46%PMCBNuvilex10.20%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionablePMCBNuvilex46.86 million6.16 millionOptionableSNYRSynergy CHC409.19 million3.99 millionN/APMCB, MAAQ, SNYR, and MRNS HeadlinesRecent News About These CompaniesSynergy CHC Expands Retail Presence in North AmericaJune 30, 2025 | tipranks.comSynergy CHC Corp. (SNYR) Stock Price Today - WSJJune 24, 2025 | wsj.comSynergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue StreamsJune 18, 2025 | finance.yahoo.comSynergy CHC Corp. Expands International Licensing Deal with Gravity Pharma to Include Turkey, Securing $2 Million in RevenueJune 18, 2025 | quiverquant.comQHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 18, 2025 | finance.yahoo.comHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 16, 2025 | insidermonkey.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 9,400 SharesJune 12, 2025 | insidertrades.comNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink’s Global ExpansionJune 11, 2025 | freep.comFNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global ExpansionJune 10, 2025 | guardonline.comGSynergy CHC Corp. Appoints Damian Marano as Vice President of Beverage to Accelerate Functional Beverage ExpansionJune 10, 2025 | quiverquant.comQSynergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global ExpansionJune 10, 2025 | globenewswire.comSynergy CHC secures $20 million loan for growth and debt repaymentJune 5, 2025 | investing.comSynergy CHC Secures $20 Million Loan AgreementJune 4, 2025 | msn.comSynergy CHC Announces New $20 Million Long-Term Credit FacilityJune 4, 2025 | globenewswire.comSNYR Synergy CHC Corp.May 30, 2025 | seekingalpha.comSynergy CHC Announces Appointment of Erik Shields as Vice President of BeverageMay 29, 2025 | finance.yahoo.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 5,000 SharesMay 22, 2025 | insidertrades.comAnalysts Offer Insights on Consumer Goods Companies: Wilmar International (OtherWLMIF) and Synergy CHC (SNYR)May 21, 2025 | theglobeandmail.comSynergy CHC Corp (SNYR) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges with ...May 16, 2025 | uk.finance.yahoo.comSynergy CHC Corp. Reports Strong Q1 2025 EarningsMay 15, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMCB, MAAQ, SNYR, and MRNS Company DescriptionsMana Capital Acquisition NASDAQ:MAAQ$4.15 -0.14 (-3.26%) As of 07/11/2025Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.Marinus Pharmaceuticals NASDAQ:MRNSMarinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Nuvilex NASDAQ:PMCB$1.06 -0.06 (-4.91%) As of 12:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Synergy CHC NASDAQ:SNYR$3.52 +0.09 (+2.62%) As of 12:27 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
